Lucid Diagnostics (LUCD) filed a shelf registration late Wednesday with the Securities and Exchange Commission for the potential secondary sale, 'from time to time,' of up to 37 million of its shares by 2024 convertible note holders.
The company closed the sale of about $22 million in principal amount of Senior Secured Convertible Notes in a private placement in November 2024. The 37 million of its shares potentially sold in secondary offerings refer to 'a reasonable estimate of the maximum number of shares issuable upon conversion of, and in payment of interest on' those notes.
Lucid said it is not selling any of its stock under the shelf registration, and will not receive any proceeds from such a sale.
'The timing and amount of any sales are within the sole discretion' of the secondary sale's stockholders, the company added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。